drugset / Trial / NCT05041972
ARX788 in Selected HER2-mutated or HER2-amplified/Overexpressed Solid Tumors (ACE-Pan Tumor-02)
Non-randomizedParallel-groupOpen-labelTreatment
Summary
A Global Phase 2 Study to Evaluate the Efficacy and Safety of ARX788 for Selected HER2-mutated or HER2-amplified/overexpressed Solid Tumors (ACE-Pan tumor-02)
Timeline
- Start
- 2021-11-05
- Primary completion
- 2022-04-20
- Completion
- 2022-04-20
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | ANVATABART OPADOTIN | Other / unclassified | — | Intravenous |
Indications
No indication recorded.